INIS

$INIS chatter on StockTwits

• 
  Mr. Wealthy Investor@LifesGoodBullish1d

  $INIS The Good (Forward-Looking Catalysts)Recalls Fully Behind Them: Capsule inventory was fully restored by late June, FDA 483/recall actions were submitted, and sales normalized in July.Cobalt Unit Recovered: The hot-cell rehabilitation was completed, returning the unit to profitability and securing $1.2M in contracted sales for the second half of 2026.Lucerno Asset Closing: Formally closed the Lucerno Dynamics acquisition ($900K for LARA® & ELLEXA® IP) to expand higher-margin medical device offerings.

  View on StockTwits ↗
• 
  Mr. Wealthy Investor@LifesGoodBullishJul 27

  $INIS been here about 5 years now and I'm still

  View on StockTwits ↗
• 
  Mr. Wealthy Investor@LifesGoodBullishJul 22

  $INIS

  View on StockTwits ↗
• 
  Mr. Wealthy Investor@LifesGoodBullishJul 13

  $INIS What they bought: They acquired the LARA System and ELLEXA Explorer software/intellectual property for $900,000. These are specialized medical tools used to monitor radiopharmaceutical delivery errors (extravasations).The Growth Driver: This technology is already used in nearly 50,000 global radiopharmaceutical administrations. Rather than relying purely on legacy contract manufacturing, Radnostix now owns a high-margin medical device portfolio. Watch for upcoming quarterly revenue numbers to see if they can successfully cross-sell this tech to their existing healthcare clients

  View on StockTwits ↗
• 
  Mike@NVDAMillionaireJun 5

  $INIS Great piece that accurately captures INIS's current position. So if you want to refresh your understanding of INIS or learn about INIS for the first time, this is essential reading. https://everyticker.com/quote/INIS/analysis/radnostix-s-radioactive-moat-meets-financial-distress-a-0-07-bet-on-nuclear-medicine-s-niche-infrastructure-nasdaq-inis

  View on StockTwits ↗
• 
  Mr. Wealthy Investor@LifesGoodBullishJun 1

  $INIS I'm

  View on StockTwits ↗
• 
  Mr. Wealthy Investor@LifesGoodBullishApr 29

  $INIS Google the company and you will see this is a real company with real products

  View on StockTwits ↗
• 
  Mr. Wealthy Investor@LifesGoodBullishApr 11

  $INIS this just a ticking time bomb

  View on StockTwits ↗
• 
  The Investment Log@TILResearchApr 1

  $INIS has now released their 10-K if anybody else was waiting!

  View on StockTwits ↗
• 
  The Investment Log@TILResearchMar 30

  I'm surprised that we haven't seen a 10-K from $INIS yet for 2025. Seems like it is getting kind of overdue, but maybe this is because of how much they were focusing on the DUF6 sale termination. Hopefully will come early in April

  View on StockTwits ↗
• 
  The Investment Log@TILResearchMar 20

  $INIS Last post about this. I wrote my thoughts in a new post that is more complete than these snippets. TLDR: it might still be a good investment, but there are a lot of issues with the balance sheet that need to be addressed: https://www.theinvestmentlog.com/posts/inis/2026-03-19 I think this company will end up being owned by the board unless they find a new entity to acquire DUF6. It should at least help that people know it's for sale now

  View on StockTwits ↗
• 
  The Investment Log@TILResearchMar 17

  $INIS I guess the spin is that now that they aren't selling their DUF6 asset to American Fuel, they can sell it for more money? I hope this works out, but I'm skeptical. We'll see, the market seems to like this news

  View on StockTwits ↗
• 
  The Investment Log@TILResearchBearishMar 16

  $INIS I have also had troubles getting any sort of response from investor relations. A company like this really needs to learn to communicate better with shareholders

  View on StockTwits ↗
• 
  The Investment Log@TILResearchBearishMar 16

  $INIS terminated the asset sale of DUF6. This seems like a much less interesting company when they have this anchor tied to them. Hopefully they can find another buyer now that they have somewhat proven out the process. My concern is that the company is going to wipe out equity holders and end up with the debt holders taking over. Would have been great to get this cash influx so they could clean up the balance sheet

  View on StockTwits ↗
• 
  Mr. Wealthy Investor@LifesGoodBullishMar 6

  $INIS My Overall OpinionINIS (Radnostix) shows some positive momentum: revenue growth, margin expansion, and a pivot to high-potential areas like theranostics and medical devices, which align with aging populations and advances in nuclear medicine. The asset sale could inject significant cash (~6x current cash reserves), potentially funding R&D or debt reduction, and the name change signals a clearer healthcare focus. If executed well, this could position it for profitability in a niche market with barriers to entry (e.g., regulatory expertise).However, it's a highly speculative investment. The company is tiny, with razor-thin profits, heavy debt relative to equity, and a history of losses that could recur if supplies falter or regulations tighten. Liquidity is precarious, and the registration revocation adds red flags—reduced transparency could mean hidden problems or just administrative fallout from the rebrand. At $0.09/share, it's cheap, but volatility is high, trading volume low,

  View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.